Found 8 matching trials
MB-CART2019.1 in Refractory Multiple Sclerosis
PHASE1The goal of this trial is to assess the feasibility, safety and preliminary...
Location
Charité Universitätsmedizin Berlin
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL
PHASE2FRONTIER is a prospective, single arm, open label, multi-center, Phase II s...
Location
Multiple Locations
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
PHASE1This is a prospective, multi-center, open phase I/II trial to evaluate feas...
Location
Klinikum Augsburg, II. Med. Klinik Haematologie / Onkologie
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
PHASE2This is a single-arm, multi-center, open-label Phase II study to determine ...
Location
Hôpital Robert Debré
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NAThe goal of this Long-Term Follow-Up Trial is to assess long-term safety an...
Location
Charité Universitätsmedizin Berlin
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
PHASE2In the current protocol version, there are two parts. Part I is a pivotal P...
Location
LKH - Medizinische Universitaet Graz
DALY II Japan/MB-CART2019.1 for DLBCL
PHASE2DALY II Japan is a phase II, multi-center, single arm study to evaluate the...
Location
National Cancer Center Hospital
DALY II USA/ MB-CART2019.1 for DLBCL
PHASE2DALY II USA is a phase II, multi-center, single arm study to evaluate the e...
Location
University of Alabama at Birmingham